Jade Biosciences, Inc.
Support and Resistance Levels
Past performance
News About JBIO
All events for JBIO
All deals for JBIO
Financial Ratios
Financial Statements
JBIO vs Sector & Peers
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003. Website jadebiosciences.com
Headquarters Waltham, MA, US